Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick Taylor

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Crohn'S & Colitis|September 14, 2023
Validation of the IBD-Control Questionnaire across different sociodemographic and clinical subgroups: secondary analysis of a nationwide electronic surveyGerum G Gebeyehu, Frederick Taylor, Liz Dobson, et al.
Therapeutic Advances in Gastroenterology|June 4, 2026
The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomesKeith Bodger, Cheryl Booker, Frederick Taylor, et al.
Therapeutic Advances in Gastroenterology|July 30, 2025
Real-world outcomes from the UK IBD Registry on second-line biologic therapy following anti-TNF exposure in Crohn's disease: results from the BISCUITS studyFrederick Taylor, Giorgio Bartalucci, Catherine Gleave, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Crohn'S & Colitis|September 14, 2023
Validation of the IBD-Control Questionnaire across different sociodemographic and clinical subgroups: secondary analysis of a nationwide electronic surveyGerum G Gebeyehu, Frederick Taylor, Liz Dobson, et al.
Therapeutic Advances in Gastroenterology|June 4, 2026
The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomesKeith Bodger, Cheryl Booker, Frederick Taylor, et al.
Therapeutic Advances in Gastroenterology|July 30, 2025
Real-world outcomes from the UK IBD Registry on second-line biologic therapy following anti-TNF exposure in Crohn's disease: results from the BISCUITS studyFrederick Taylor, Giorgio Bartalucci, Catherine Gleave, et al.
Pageof 2